je.st
news
Tag: findings
Boise | 6-30-16 | 626 N Skidmore St |Type II Historic Resource Review w/Modifications Appealed to Landmark Commission Final Findings | LU 15-276093 HRM
2016-06-30 23:58:39| PortlandOnline
PDF Document, 1,109kbCategory: Northeast Coalition of Neighbors Decisions
Tags: type
review
final
resource
Boise | 6-30-16 | 626 N Skidmore St | Type II Historic Resource Review w/Modifications Appealled to Landmark Commission Final Findings | LU 15-276093 HRM
2016-06-29 20:15:03| PortlandOnline
PDF Document, 1,109kbCategory: Northeast Coalition of Neighbors Decisions
Tags: type
review
final
resource
Could climate change affect your day fishing? Ontario researcher presents findings in Washington DC
2016-06-28 12:02:00| Climate Ark Climate Change & Global Warming Newsfeed
CBC.ca: A Thunder Bay researcher with Ontario's Ministry of Natural Resources and Forestry has just returned from briefing Senate staff in Washington, D.C. on the potential impacts of climate change on North America's recreational fishery. The invitation to speak on Capitol Hill came from the United States Geological Survey, following his participation in a number of conferences and workshops on the issue, says Len Hunt, who holds a PhD in geography and environmental studies from Wilfrid Laurier University....
Tags: day
change
washington
dc
Portland Downtown | 6-24-16 | 1133 SW Market St | Design w/Modifications & Adjustment Review FINAL FINDINGS | LU 16-104926 DZM AD / PC # 14-247316
2016-06-24 01:08:33| PortlandOnline
PDF Document, 1,714kbCategory: Neighbors West/Northwest Decisions
Updated Findings from KEYNOTE-012 for KEYTRUDA (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer
2016-06-06 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Responding with KEYTRUDA; Results Confirm Findings from KEYNOTE-012 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data with KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy from two studies (KEYNOTE-012 and KEYNOTE-055) in heavily pre-treated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Data are being presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] next »